| Sector |
Trading
|
Compare with Sector peers |
| Industry |
Trading
|
Compare with Industry peers |
| Website | http://www.vivanzabiosciences.com | |
| Market Cap | 75.20 Cr. | |
| Enterprise Value(EV) | 82.95 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.13 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | 149.80 | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 35.68 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 1.05 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 17.93 | Calculated using Price: 18.80 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 4.00 Cr. | 40,000,000 Shares |
| FaceValue | 1 | |
| Company Profile | ||
| The company is engaged in the business of business of Pharmaceutical Products. | ||
| 1 Day |
|
|
| 1 Week |
|
-4.76% |
| 1 Month |
|
+24.50% |
| 3 Month |
|
+20.51% |
| 6 Month |
|
+21.29% |
| 1 Year |
|
-0.32% |
| 2 Year |
|
+43.95% |
| 5 Year |
|
+168.57% |
| 10 Year |
|
+557.34% |
| 7 years | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | -242.60 | -17.54 | 5.66 | -12.56 | -6.46 | 2.41 | 10.01 | |
| Return on Capital Employed (%) | -11.38 | -10.82 | 12.73 | -0.40 | 5.74 | 17.11 | 15.64 | |
| Return on Assets (%) | -9.49 | -7.99 | 2.37 | -4.15 | -1.75 | 0.72 | 3.13 |
| Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 0 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | |
| Non Curr. Liab. | 0 | 1 | 1 | 0 | 3 | 2 | |||
| Curr. Liab. | 1 | 3 | 6 | 7 | 9 | 5 | 7 | 8 | |
| Minority Int. | |||||||||
| Equity & Liab. | 1 | 7 | 10 | 11 | 12 | 8 | 13 | 13 | |
| Non Curr. Assets | 1 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
| Curr. Assets | 0 | 4 | 7 | 8 | 9 | 5 | 10 | 10 | |
| Misc. Exp. not W/O | |||||||||
| Total Assets | 1 | 7 | 10 | 11 | 12 | 8 | 13 | 13 |
| Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 3 | 6 | 3 | 10 | 10 | 10 | 15 | ||
| Other Income | 0 | 1 | 1 | 1 | 1 | ||||
| Total Income | 4 | 6 | 3 | 10 | 10 | 11 | 16 | ||
| Total Expenditure | 0 | -4 | -6 | -3 | -10 | -10 | -10 | -15 | |
| PBIDT | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Depreciation | 0 | 0 | 0 | ||||||
| Taxation | 0 | 0 | |||||||
| Exceptional Items | 0 | ||||||||
| PAT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Minority Interest | |||||||||
| Share Associate | |||||||||
| Other Related Items | |||||||||
| Consolidated Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Particulars | 7 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | -2 | 0 | 1 | 3 | -3 | |||
| Cash Fr. Inv. | 2 | 0 | ||||||
| Cash Fr. Finan. | 0 | -1 | -1 | -3 | 2 | |||
| Net Change | 0 | -1 | 0 | 0 | 0 | |||
| Cash & Cash Eqvt | -2 | -3 | -3 | -3 | -3 |
|
Wed, 29 Mar 2023
Announcement under Regulation 30 (LODR)-Meeting Updates We wish to inform you that pursuant to Regulation 25(3) and other applicable regulation of SEBI (LODR) and Schedule IV of the Companies Act 2013 and other applicable provisions of the Companies Act 2013 a separate meeting of Independent Director is held on today i.e. March 29 2023 and transacted the following businesses:1. Reviewed the performance of non-independent directors and the board of directors as whole of the Company.2. Reviewed the performance of the Chairperson of the company taking into account the views of Executive Directors and Non-Executive Directors.3. Assessed the quality quantity and timelines of flow of information between the Management of the Company and the Board of directors to effectively and reasonably perform their duties. |
|
Tue, 28 Mar 2023
Closure of Trading Window Pursuant to Clause 4 of Schedule B of the SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time and in accordance with the Companys Code of conduct to regulate monitor and report trades in securities by Directors Promoters Designated Persons and Specified Connected Persons of the Company this is to inform that the trading window for dealing in Equity Shares of the Company by the Insiders will be closed from April 1 2023 till 48 hours after the declaration of Financial Results for the Quarter and Year ended on 31st March 2023. |
|
Tue, 28 Mar 2023
Board Meeting Intimation for Approval Of The Audited Standalone And Consolidated Financial Statements And Financial Results Of The Company For The Quarter And Year Ended March 31 2023. Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2023 inter alia to consider and approve 1. Audited standalone and consolidated financial statements and financial results of the Company for the quarter and year ended March 31 2023;2. Appointment of Independent Director on the Board of the Company;3. Appointment of Managing Director of the Company; |
| Mon, 27 Mar 2023 |
Close Crossing Last Week Low
|
Opening at High
|
Opening at Low
|
Opening at High for 3 days
|
Closing Below Previous Low
|
Equities
M.F.
Sectors